This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Aug;68(2):336.

doi: 10.1016/j.eururo.2015.03.012.

Re: Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Francesco Greco¹, Vincenzo Mirone²

Affiliations

Affiliations

¹ Department of Urology and Mini-invasive Surgery, Romolo Hospital, Rocca di Neto, Crotone, Italy; Department of Urology, University Federico II, Naples, Italy. Electronic address: francesco_greco@ymail.com.
² Department of Urology, University Federico II, Naples, Italy.

PMID: 26149726
DOI: 10.1016/j.eururo.2015.03.012

Comment

Re: Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Francesco Greco et al. Eur Urol. 2015 Aug.

. 2015 Aug;68(2):336.

doi: 10.1016/j.eururo.2015.03.012.

Authors

Francesco Greco¹, Vincenzo Mirone²

Affiliations

¹ Department of Urology and Mini-invasive Surgery, Romolo Hospital, Rocca di Neto, Crotone, Italy; Department of Urology, University Federico II, Naples, Italy. Electronic address: francesco_greco@ymail.com.
² Department of Urology, University Federico II, Naples, Italy.

PMID: 26149726
DOI: 10.1016/j.eururo.2015.03.012

No abstract available

PubMed Disclaimer

Comment on

Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Karam JA, et al. Eur Urol. 2014 Nov;66(5):874-80. doi: 10.1016/j.eururo.2014.01.035. Epub 2014 Feb 7. Eur Urol. 2014. PMID: 24560330 Free PMC article. Clinical Trial.

Similar articles

Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Karam JA, et al. Eur Urol. 2014 Nov;66(5):874-80. doi: 10.1016/j.eururo.2014.01.035. Epub 2014 Feb 7. Eur Urol. 2014. PMID: 24560330 Free PMC article. Clinical Trial.
Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better?
Leiter A, Galsky MD. Leiter A, et al. Eur Urol. 2014 Nov;66(5):881-3. doi: 10.1016/j.eururo.2014.02.059. Epub 2014 Mar 11. Eur Urol. 2014. PMID: 24631407 No abstract available.
Axitinib dose titration: what's the limiting factor?
Buti S, Porta C. Buti S, et al. Lancet Oncol. 2013 Nov;14(12):1152-4. doi: 10.1016/S1470-2045(13)70489-3. Epub 2013 Oct 18. Lancet Oncol. 2013. PMID: 24140182 No abstract available.
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Umeyama Y, Shibasaki Y, Akaza H. Umeyama Y, et al. Future Oncol. 2017 Sep;13(21):1839-1852. doi: 10.2217/fon-2017-0104. Epub 2017 Jul 14. Future Oncol. 2017. PMID: 28707479 Review.
Common questions regarding clinical use of axitinib in advanced renal cell carcinoma.
Borst DL, Arruda LS, MacLean E, Pithavala YK, Morgado JE. Borst DL, et al. Am J Health Syst Pharm. 2014 Jul 1;71(13):1092-6. doi: 10.2146/ajhp130581. Am J Health Syst Pharm. 2014. PMID: 24939498 Review.

See all similar articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information